Search Results

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

The 14th "Charm of Nuclear Power" National Nuclear Science Summer Camp Concludes in Shanghai

On August 1, the 14th "Charm of Nuclear Power" National Nuclear Science Summer Camp concluded in Shanghai. The event was jointly hosted by the Chinese Nuclear Society and China National Nuclear Power Co., Ltd. (CNNP), organized by the Nuclear Power Operation Research Institute, and co-organized by Qinshan Nuclear Power. The closing activities focused on public communication of nuclear energy, science popularization brand building, and youth nuclear science communication, presenting the achievements of nuclear science popularization and the development of the nuclear industry through thematic sharing sessions, corporate standard releases, science IP launches, and nuclear science explainer demonstrations. At the public communication themed event held on the closing day, Zhang Jing, Director of the Division for Europe and Central Asia at the International Atomic Energy Agency (IAEA), Jiang Yi, Member of the Party Leadership Group and Head of the Discipline Inspection Group of the Ministry of Ecology and Environment's East China Regional Office of Nuclear and Radiation Safety Supervision, Gao Keli, Deputy Secretary-General of the Chinese Nuclear Society, and a relevant official from CNNC's Shanghai Market Development Department delivered speeches respectively. Representatives from the China Atomic Energy Authority, the National Energy Administration, the World Association of Nuclear Operators (WANO) Shanghai Office, Tsinghua University, Shanghai Jiao Tong University, the Shanghai Nuclear Power Office, as well as industry experts, science popularization workers, and all summer camp participants attended the event. A relevant official from CNNP delivered the closing address on behalf of the organizers.

2026-08-04

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

Bolivia Advances Legislative Process for Peaceful Nuclear Technology Applications

EL ALTO, Bolivia, July 29 - The Bolivian Nuclear Energy Agency (ABEN) recently held working exchanges with relevant committees of the Plurinational Legislative Assembly to discuss the reactivation of related legislative agendas, focusing on the continued advancement of Bolivia's nuclear energy program and peaceful nuclear technology application projects. René Soria Sausedo, Executive Director of ABEN, stated that as the primary operating entity of Bolivia's nuclear program, ABEN bears the responsibility of driving the implementation of peaceful nuclear technology application projects. These efforts require modern legal instruments to define institutional mandates, technical standards, and the fundamental legal framework for project development. The parliamentary delegation, led by the President of the International Policy and Migration Protection Committee, visited ABEN facilities...

2026-08-03

The 14th "Charm of Nuclear" Nuclear Science Summer Camp Opens at Shanghai Jiao Tong University

On July 31, the 14th "Charm of Nuclear" National Nuclear Science Summer Camp, co-hosted by the Chinese Nuclear Society and China National Nuclear Power Co., Ltd., organized by the Nuclear Power Operation Research Institute and co-organized by Qinshan Nuclear Power, opened at the Gaotian Hall on the Minhang Campus of Shanghai Jiao Tong University. The opening ceremony also featured lectures by academicians and experts, providing a high-quality platform for young people to explore nuclear science and technology through diverse and enriching science communication formats. Chai Zhifang, academician of the Chinese Academy of Sciences and honorary director of the State Key Laboratory of Radiological Medicine and Radiation Protection at Soochow University, Gao Keli, deputy secretary-general of the Chinese Nuclear Society, and relevant officials from the CNNC Shanghai Market Development Department, the Nuclear Power Operation Research Institute, and the School of Mechanical Engineering at Shanghai Jiao Tong University...

2026-08-03

Romanian Army Deploys on the Danube to Protect Nuclear Power Plant Operations

The Romanian Ministry of National Defense announced that the Romanian Army has been mobilized to protect the operation of the Cernavodă Nuclear Power Plant and conduct hydrographic measurements on the Danube River. The Ministry stated that this measure was taken in response to the current critical situation on the Danube to ensure the safe operation of the nuclear power plant. The military action aims to obtain the technical data required for the construction of a mobile weir that will redirect a portion of the Danube's flow into the Old Danube. Naval forces are conducting measurements at kilometers 345 to 346 of the Danube, in the area where the Bala branch converges, to determine the parameters needed for implementing the weir. Military experts are analyzing the riverbed and water depth, and transmitting the collected data to the relevant administrative authorities. The Ministry emphasized that these measures...

2026-08-02

Thor Medical Launches Commercial Production of Lead-212 at AlphaOne Facility

Thor Medical ASA announced on July 31 that commercial production has commenced at its industrial-scale AlphaOne production facility located in the Herøya industrial park. The facility will produce lead-212 (Pb-212) and its precursors thorium-228 (Th-228) and radium-224 (Ra-224) to support demand related to radiopharmaceuticals and targeted cancer radiotherapy. According to the company, Thor Medical has signed supply agreements with multiple types of customers across the radiopharmaceutical value chain, including startup biotechnology companies, contract development and manufacturing organizations (CDMOs), and global pharmaceutical companies. The company expects the AlphaOne facility to deliver its first products to customers in August 2026. AlphaOn...

2026-08-01

Third fuel debris retrieval test at Fukushima Daiichi Unit 2 postponed due to robotic arm malfunction

The robot used by Tokyo Electric Power Company (TEPCO) for the third experimental fuel debris retrieval at Fukushima Daiichi Nuclear Power Station Unit 2 malfunctioned during an on-site operational test, forcing the cancellation of the plan originally scheduled to start after July 2026 if all went well. The company stated it will reassess the relevant procedures. The malfunction occurred in part of the large robotic arm equipment used to collect fuel debris. During an operational test in the reactor building of Unit 2, TEPCO found an abnormality in one of the motors driving the robotic arm, causing the brake to fail to release and the arm to be unable to extend. The company is currently studying the replacement of the faulty motor. The third experimental retrieval plan was to use a large robotic arm...

2026-07-31

Factory Acceptance Test Completed for TM020 RF Cavity of Super Tau-Charm Facility

The 500MHz TM020 normal-conducting RF cavity, a key component of the STCF accelerator constructed by Lanzhou Taiji, passed its factory acceptance test on July 28, 2026. This marks a significant milestone in the key technology research project for the Super Tau-Charm Facility (STCF), a new-generation electron-positron collider led by the University of Science and Technology of China. The review meeting brought together experts from the Institute of High Energy Physics of the Chinese Academy of Sciences, Shanghai Advanced Research Institute of the Chinese Academy of Sciences, Chongqing University, Tsinghua University, the University of Science and Technology of China, and Dongsheng Fusion (Shanghai) Technology Co., Ltd. The expert panel conducted a comprehensive and rigorous review of the RF cavity (a 1200mm large-diameter cavity), including its structural design, secondary vacuum brazing, precision machining methods, vacuum performance, and cold test results, and unanimously agreed that all indicators met the design requirements. The measured unloaded quality factor (Q₀) reached 56900 (design value 61500), placing its performance at a leading level among similar high-performance normal-conducting RF cavities in China.

2026-07-31

Kazakhstan advances the use of radiation technology for agricultural preservation and advanced wastewater treatment.

Sayabek Sakhiyev, Director of the Institute of Nuclear Physics of Kazakhstan, recently stated that radiation technology holds promise for helping Kazakhstan reduce post-harvest losses, extend the shelf life of agricultural products, and facilitate advance

2026-07-27

Nuclear technology helps boost disease resistance and food security in Latin American rainbow trout farming.

Rainbow trout farming in Latin America is shifting from a model driven by traditional experience to one supported by science and technology. Widely farmed in freshwater rivers, lakes, lagoons, and coastal net pens, rainbow trout constitute a vital part of

2026-07-27